Latest News

Date Title Topic
04 Dec 2013 Onartuzumab in Combination with Erlotinib in Patients with Advanced NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
02 Dec 2013 Exome Sequencing Identifies Frequent Inactivating Mutations in Intrahepatic Cholangiocarcinomas Translational research - Gastrointestinal cancers
29 Nov 2013 European Medicines Agency Recommends Changes in Use of Ponatinib in Order to Minimise Risk of Thrombosis Anticancer agents & Biologic therapy
28 Nov 2013 ESMO Press Release: Untreated Cancer Pain a ‘Scandal of Global Proportions,’ Survey Shows Palliative and supportive care
27 Nov 2013 European Medicines Agency Issues Positive Recommendation on Generic Zoledronic Acid Palliative and supportive care
26 Nov 2013 European Medicines Agency Recommends Extension of Indications for Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) Gastrointestinal cancers - Anticancer agents & Biologic therapy
26 Nov 2013 European Medicines Agency Recommends Refusal of the Marketing Authorisation for Masitinib Sarcomas - Anticancer agents & Biologic therapy
Specialist in Haematology/Oncology, Luxembourg
25 Nov 2013 Immuno-Oncology 2013 Webcasts
25 Nov 2013 European Medicines Agency Recommends Change in Indication for Cetuximab to RAS Wild-type Metastatic Colorectal Cancer Gastrointestinal cancers - Anticancer agents & Biologic therapy
21 Nov 2013 Continuation of Bevacizumab with Second-Line Chemotherapy after the Standard First-Line Bevacizumab-Containing Therapy in mCRC: What is the value of KRAS status? Gastrointestinal cancers
OncologyPRO
20 Nov 2013 Clinical Predictors of Acute Urinary Symptoms after Radiotherapy for Prostate Cancer Genitourinary cancers
19 Nov 2013 ESMO Press Release: ESMO Spearheads International Collaboration to Assure Patient Access to Safe and Effective Cancer Medicines
19 Nov 2013 Screening Programme for Efficient Clinical Trial Access – Lung Cancer Biomarker Screening Platform Personalised medicine - Lung and other thoracic tumours